0001209191-21-017543.txt : 20210303 0001209191-21-017543.hdr.sgml : 20210303 20210303203903 ACCESSION NUMBER: 0001209191-21-017543 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20210301 FILED AS OF DATE: 20210303 DATE AS OF CHANGE: 20210303 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Cappel Markus J. CENTRAL INDEX KEY: 0001422995 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-35420 FILM NUMBER: 21712108 MAIL ADDRESS: STREET 1: 850 MAUDE AVENUE CITY: MOUNTAIN VIEW STATE: CA ZIP: 94043 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: ChemoCentryx, Inc. CENTRAL INDEX KEY: 0001340652 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 943254365 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 850 MAUDE AVENUE CITY: MOUNTAIN VIEW STATE: CA ZIP: 94043 BUSINESS PHONE: 650-210-2900 MAIL ADDRESS: STREET 1: 850 MAUDE AVENUE CITY: MOUNTAIN VIEW STATE: CA ZIP: 94043 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2021-03-01 0 0001340652 ChemoCentryx, Inc. CCXI 0001422995 Cappel Markus J. C/O CHEMOCENTRYX, INC. 850 MAUDE AVENUE MOUNTAIN VIEW CA 94043 0 1 0 0 Chief Bus. Officer & Treasurer Common Stock 2021-03-01 4 M 0 5417 6.62 A 91243 D Common Stock 2021-03-01 4 M 0 11667 10.86 A 102910 D Common Stock 2021-03-01 4 M 0 16008 11.02 A 118918 D Common Stock 2021-03-01 4 S 0 7053 67.6821 D 111865 D Common Stock 2021-03-01 4 S 0 20680 68.5129 D 91185 D Common Stock 2021-03-01 4 S 0 5359 69.0865 D 85826 D Stock Option (right to buy) 6.62 2021-03-01 4 M 0 5417 D 2027-02-28 Common Stock 5417 18958 D Stock Option (right to buy) 10.86 2021-03-01 4 M 0 11667 D 2028-03-05 Common Stock 11667 24792 D Stock Option (right to buy) 11.02 2021-03-01 4 M 0 16008 D 2029-03-04 Common Stock 16008 42292 D The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Reflects the weighted average sale price of the shares sold. The shares were sold in multiple trades at prices ranging from $66.99 to $67.98 per share. The Reporting Person will provide to the SEC staff, the issuer or a security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price. Reflects the weighted average sale price of the shares sold. The shares were sold in multiple trades at prices ranging from $68.00 to $68.98 per share. The Reporting Person will provide to the SEC staff, the issuer or a security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price. Reflects the weighted average sale price of the shares sold. The shares were sold in multiple trades at prices ranging from $69.00 to $69.24 per share. The Reporting Person will provide to the SEC staff, the issuer or a security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price. As of March 1, 2021, and prior to this transaction, the exercised options were fully vested. Not applicable. /s/ Susan M. Kanaya, as Attorney-in-Fact 2021-03-03